Viveve Medical Statistics
Total Valuation
Viveve Medical has a market cap or net worth of 1,075.
| Market Cap | 1,075 |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Viveve Medical has 10.75 million shares outstanding.
| Current Share Class | 10.75M |
| Shares Outstanding | 10.75M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.23% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.00 |
| PB Ratio | 0.00 |
| P/TBV Ratio | 0.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.89, with a Debt / Equity ratio of 5.08.
| Current Ratio | 0.89 |
| Quick Ratio | 0.62 |
| Debt / Equity | 5.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.36 |
| Interest Coverage | -19.01 |
Financial Efficiency
Return on equity (ROE) is -210.99% and return on invested capital (ROIC) is -79.78%.
| Return on Equity (ROE) | -210.99% |
| Return on Assets (ROA) | -62.13% |
| Return on Invested Capital (ROIC) | -79.78% |
| Return on Capital Employed (ROCE) | -1,605.32% |
| Revenue Per Employee | 145,234 |
| Profits Per Employee | -598,617 |
| Employee Count | 47 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 3.03 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -75.00% in the last 52 weeks. The beta is -57.34, so Viveve Medical's price volatility has been lower than the market average.
| Beta (5Y) | -57.34 |
| 52-Week Price Change | -75.00% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 44.44 |
| Average Volume (20 Days) | 1,899 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.86 |
Income Statement
In the last 12 months, Viveve Medical had revenue of 6.83 million and -28.14 million in losses. Loss per share was -2.65.
| Revenue | 6.83M |
| Gross Profit | 1.12M |
| Operating Income | -21.14M |
| Pretax Income | -22.73M |
| Net Income | -28.14M |
| EBITDA | -20.34M |
| EBIT | -21.14M |
| Loss Per Share | -2.65 |
Balance Sheet
The company has 5.91 million in cash and 6.01 million in debt, giving a net cash position of -107,000 or -0.01 per share.
| Cash & Cash Equivalents | 5.91M |
| Total Debt | 6.01M |
| Net Cash | -107,000 |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | 1.18M |
| Book Value Per Share | 0.11 |
| Working Capital | -1.23M |
Cash Flow
In the last 12 months, operating cash flow was -16.23 million and capital expenditures -595,000, giving a free cash flow of -16.83 million.
| Operating Cash Flow | -16.23M |
| Capital Expenditures | -595,000 |
| Free Cash Flow | -16.83M |
| FCF Per Share | -1.56 |
Margins
| Gross Margin | 16.39% |
| Operating Margin | -309.73% |
| Pretax Margin | -333.04% |
| Profit Margin | n/a |
| EBITDA Margin | -297.91% |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Viveve Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -33.26% |
| Shareholder Yield | -33.26% |
| Earnings Yield | -2,617,209.30% |
| FCF Yield | -1,565,302.33% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 2, 2020. It was a reverse split with a ratio of 0.1.
| Last Split Date | Dec 2, 2020 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Viveve Medical has an Altman Z-Score of -34.43 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -34.43 |
| Piotroski F-Score | 3 |